Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
02 Januar 2024 - 10:21PM
Edgar (US Regulatory)
|
UNITED STATES |
OMB APPROVAL |
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
OMB Number:
Expires: |
3235-0058
April 30, 2025 |
|
|
Estimated average burden hours |
|
|
per response |
2.50 |
|
FORM 12b-25
|
SEC FILE NUMBER
000-55072 |
|
NOTIFICATION OF LATE FILING |
CUSIP NUMBER
|
(Check one): |
[X] Form 10-K |
[_] Form 20-F |
[_] Form 11-K |
[_] Form 10-Q |
[_] Form 10-D |
[_] Form N-CEN |
[_] Form N-CSR |
|
For Period Ended: September 30, 2023 |
|
|
|
[_] Transition Report on Form 10-K |
|
[_] Transition Report on Form 20-F |
|
[_] Transition Report on Form 11-K |
|
[_] Transition Report on Form 10-Q |
|
For the Transition Period Ended:__________________________________ |
Nothing in this form shall be construed to imply
that the Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:
PART I — REGISTRANT INFORMATION
GlobeStar Therapeutics Corporation |
Full Name of Registrant |
|
|
Former Name if Applicable |
|
719 Jadwin Avenue |
Address of Principal Executive Office (Street and Number) |
|
Richland, WA 99352 |
City, State and Zip Code |
PART II — RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
|
(a) |
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable
effort or expense; |
[X] |
(b) |
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion
thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition
report on Form 10-Q, or subject distribution report on Form 10-D,or portion thereof, will be filed on or before the fifth calendar day
following the prescribed due date; and |
|
(c) |
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART III — NARRATIVE
GlobeStar Therapeutics Corporation (the “Company”) is
unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the year ended September 30, 2023 (the
“Form 10-K”) within the prescribed time period because the Company will need additional time to finalize the Company’s annual
financial statements for the year ended September 30, 2023 to be included with the Form 10-K. The Company plans to file its Form
10-K within the additional 15 days allowed to complete and file the Form 10-K.
PART IV — OTHER INFORMATION
(1) |
Name and telephone number of person to contact in regard to this notification |
|
James C. Katzaroff |
|
509 |
|
531-1671 |
|
(Name) |
|
(Area Code) |
|
(Telephone Number) |
(2) |
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). |
(3) |
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? |
|
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. |
|
|
|
|
|
GlobeStar Therapeutics Corporation |
|
|
(Name of Registrant as Specified in Charter) |
|
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized. |
Date |
January 2, 2024 |
|
By |
/s/ James C. Katzaroff |
|
|
|
|
James C. Katzaroff, Chief Executive Officer |
- 2 -
Globestar Therapeutics (PK) (USOTC:GSTC)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Globestar Therapeutics (PK) (USOTC:GSTC)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
Echtzeit-Nachrichten über Globestar Therapeutics Corporation (PK) (OTCMarkets): 0 Nachrichtenartikel
Weitere Globestar Therapeutics Corporation (PK) News-Artikel